Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations

被引:32
|
作者
Shen, Jie [1 ]
Lu, Guang Wei [2 ]
Hughes, Patrick [3 ]
机构
[1] Allergan Plc, Clin Pharmacol Nonclin & Translat Sci, 2525 Dupont Dr, Irvine, CA 92612 USA
[2] TWi Pharmaceut Inc, Ophthalm Prod Dev, Taipei, Taiwan
[3] Glaukos Corp, Appl Res, San Clemente, CA USA
关键词
formulation; ocular; pharmacokinetic; pharmacodynamic; sustained release; targeted delivery; EPISCLERAL CYCLOSPORINE IMPLANT; IN-VITRO; SUBCONJUNCTIVAL BEVACIZUMAB; SUSTAINED-RELEASE; VIVO EVALUATION; AQUEOUS-HUMOR; GLAUCOMA; PHARMACOKINETICS; LATANOPROST; ABSORPTION;
D O I
10.1007/s11095-018-2498-y
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of ophthalmic drug delivery systems is a long and comprehensive process including research, nonclinical, and clinical development stages. It is critical to understand the similarity and differences between animal models and patients. There are many anatomically and physiologically important parameters for targeted drug delivery into eyes. This paper reviews the constraints to various routes of ocular drug delivery and discusses the respective pharmacokinetic considerations, to lay the foundation for formulation approaches pharmaceutical scientists can use to maximize successful drug delivery for each route. The overall goal is to give both researchers and drug developers a better understanding of ocular drug delivery and offer tools to successfully develop new medicines that will fulfil unmet medical needs and improve patients' quality of life.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations
    Jie Shen
    Guang Wei Lu
    Patrick Hughes
    [J]. Pharmaceutical Research, 2018, 35
  • [2] OCULAR DRUG DELIVERY - PHARMACOKINETIC CONSIDERATIONS
    SCHOENWALD, RD
    [J]. CLINICAL PHARMACOKINETICS, 1990, 18 (04) : 255 - 269
  • [3] Pharmacokinetic considerations for targeted drug delivery
    Yamashita, Fumiyoshi
    Hashida, Mitsuru
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) : 139 - 147
  • [4] TARGETED DRUG DELIVERY - SOME PHARMACOKINETIC CONSIDERATIONS
    LEVY, G
    [J]. PHARMACEUTICAL RESEARCH, 1987, 4 (01) : 3 - 4
  • [5] Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution
    Takakura, Y
    Hashida, M
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (06) : 820 - 831
  • [6] Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems
    Glassman, Patrick M.
    Muzykantov, Vladimir R.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (03): : 570 - 580
  • [7] A pharmacokinetic model for ocular drug delivery
    Tojo, K
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2004, 52 (11) : 1290 - 1294
  • [8] Therapeutic drug monitoring of antifungals: Pharmacokinetic and pharmacodynamic considerations
    Smith, Deannina
    Andes, David
    [J]. THERAPEUTIC DRUG MONITORING, 2008, 30 (02) : 167 - 172
  • [9] CIGARETTES AND DRUG-THERAPY - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
    MILLER, LG
    [J]. CLINICAL PHARMACY, 1990, 9 (02): : 125 - 135
  • [10] Paliperidone microemulsion for nose-to-brain targeted drug delivery system: pharmacodynamic and pharmacokinetic evaluation
    Patel, Mrunali R.
    Patel, Rashmin B.
    Bhatt, Kashyap K.
    Patel, Bharat G.
    Gaikwad, Rajiv V.
    [J]. DRUG DELIVERY, 2016, 23 (01) : 346 - 354